Several private and public organizations join efforts in the LundaGUARD consortium aimed at responding to present and future threats from infectious agents. The consortium consists of partners with complementary capabilities and in-depth expertise
in structure-based drug discovery.
The project will leverage the partners ́ platform for accelerated drug discovery towards a “weak spot” in the Sars-CoV-2 virus replication machinery (1). The effort is expected to result in novel candidate drugs specifically for treating Covid-19 patients, but it also represents a versatile tool for future and hitherto unknown threats.
The consortium was put together by Dr. Wolfgang Knecht, Manager of LP3, the Protein Production Platform at Lund University. It includes the Swedish national facility MAX IV and the international facility European Spallation Source, ESS; two flagships of large-scale research infrastructure for structural biology located in Lund, Sweden. SARomics Biostructures, in collaboration with Read Glead Discovery will provide access to the unique WAC-screening platform, which has already been validated through multiple assignments with clients. Professor Frank Kozielski's group from the University College London (UCL), School of Pharmacy, one of the most highly rated pharmacy schools in the UK, contributed the structure of COVID-19 NSP10 (1), which is the target of the present study.
LP3, MAX IV Laboratory and SARomics Biostructures are already partners in the Swedish Research Council founded FragMAX project (2).
Read press release: PRESSRELEASELUNDAGUARD.pdf